Novartis’ $1.5B ADC Acquisition Highlights Growing Pharma Demand, Benefiting VERAXA Biotech

Novartis has agreed to acquire Myricx Bio for $1.1 billion upfront, with up to $400 million in milestone payments, reflecting sustained pharmaceutical appetite for innovative antibody-drug conjugate (ADC) technologies. The deal, announced this week, provides Novartis with Myricx’s novel N-myristoyltransferase inhibitor (NMTi) payload platform and two lead ADC programs, targeting limitations in existing cancer therapies.

This transaction is the latest in a series of multibillion-dollar investments in antibody therapeutics. Recent examples include Jazz Pharmaceuticals’ collaboration with AbCellera and Gilead Sciences’ acquisition of Tubulis, alongside multiple large-scale ADC licensing agreements. Such deals demonstrate pharmaceutical companies’ commitment to securing differentiated antibody platforms that can address unmet medical needs.

VERAXA Biotech (NASDAQ: VRXA) is strategically positioned within this active partnering environment. The company is advancing proprietary antibody therapeutics spanning both ADCs and T-cell engagers (TCEs) through its patented BiTAC platform. VERAXA’s pipeline includes bispecific T cell engagers, bispecific ADCs, and other innovative formats, placing it within two therapeutic categories attracting significant pharmaceutical investment, strategic collaborations, and acquisition activity.

“The Novartis-Myricx deal is a strong indicator of the value placed on next-generation ADC technologies,” said a biotech industry analyst. “VERAXA’s BiTAC platform, which combines ADCs and TCEs, is well-aligned with the current wave of pharma interest.” VERAXA’s technology is built on scientific breakthroughs from the European Molecular Biology Laboratory (EMBL), a renowned research institution.

The company’s focus on quality-by-design principles and its rapid advancement of pipeline programs into clinical development underscore its potential to attract partnership opportunities. As the ADC market continues to expand, with projections of significant growth over the next decade, VERAXA’s platform could become a key asset for pharmaceutical companies seeking to enhance their oncology portfolios.

Forward-looking statements in this article involve risks and uncertainties, including those detailed in VERAXA’s filings with the SEC. The company undertakes no obligation to update such statements. For the latest news on VERAXA, visit the company’s newsroom at https://ibn.fm/VRXA.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Novartis’ $1.5B ADC Acquisition Highlights Growing Pharma Demand, Benefiting VERAXA Biotech.

The post Novartis’ $1.5B ADC Acquisition Highlights Growing Pharma Demand, Benefiting VERAXA Biotech appeared first on citybuzz.